The grades of five Biotechnology stocks are on the rise this week on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
Ariad Pharmaceuticals’ (NASDAQ:ARIA) grade is moving up to a B (“buy”) this week from last week’s C (“hold”). ARIAD Pharmaceuticals is an oncology company that focuses on the discovery, development, and commercialization of medicines for cancer patients. For more information, get Portfolio Grader’s complete analysis of ARIA stock.
Neurocrine Biosciences’ (NASDAQ:NBIX) ratings are looking better this week, moving up to a B from last week’s C. Neurocrine Biosciences is focused on the discovery and development of therapeutics for neuropsychiatric, neuroinflammatory, and neurodegenerative diseases and disorders. Shares of NBIX have increased 6.1% over the past month, better than the 2.3% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of NBIX stock.
This is a strong week for Array BioPharma (NASDAQ:ARRY). The company’s rating climbs to B from the previous week’s C. Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer, inflammatory and metabolic diseases. Wall Street has pushed the stock higher by 11.4% over the past month. For more information, get Portfolio Grader’s complete analysis of ARRY stock.
This week, Celldex Therapeutics (NASDAQ:CLDX) is making solid headway. The company’s rating improves to an A (“strong buy”) from last week’s B (“buy”) rating. Celldex Therapeutics is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. For more information, get Portfolio Grader’s complete analysis of CLDX stock.
This week, Insmed Inc.’s (NASDAQ:INSM) ratings are up from a C last week to a B. Insmed develops and commercializes drugs that treat metabolic diseases, endocrine disorders and oncology. Investors have pushed the stock price up 24.4% over the past month. For more information, get Portfolio Grader’s complete analysis of INSM stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.